120 related articles for article (PubMed ID: 12968626)
1. GlaxoSmithKline halts AIDS study.
Clarke B
Lancet Infect Dis; 2003 Sep; 3(9):530. PubMed ID: 12968626
[No Abstract] [Full Text] [Related]
2. Meeting notes from the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Suboptimal response to once-daily abacavir + 3TC + tenofovir.
Feinberg J
AIDS Clin Care; 2003 Nov; 15(11):94. PubMed ID: 14682272
[No Abstract] [Full Text] [Related]
3. Viread, Epivir and Ziagen combination: failure in naïve patients with a once-daily regimen.
Berger DS
Posit Aware; 2003; 14(5):51-2. PubMed ID: 14679946
[No Abstract] [Full Text] [Related]
4. Meeting notes from the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Exploring once-daily tenofovir + 3TC + abacavir: an argument for clinical-trials-based data.
Becker S; Feinberg J
AIDS Clin Care; 2003 Sep; 15(9):81. PubMed ID: 14669727
[TBL] [Abstract][Full Text] [Related]
5. Prodrug of tenofovir diphosphate approved for combination HIV therapy.
Thompson CA
Am J Health Syst Pharm; 2002 Jan; 59(1):18. PubMed ID: 11813460
[No Abstract] [Full Text] [Related]
6. Clinical update: new drugs for HIV/AIDS.
Gracia Jones S; Baggett TH
Medsurg Nurs; 1999 Apr; 8(2):108-12. PubMed ID: 10410008
[TBL] [Abstract][Full Text] [Related]
7. Failure of combination abacavir + tenofovir + lamivudine (3TC).
AIDS Treat News; 2003 Jul; (393):2. PubMed ID: 14679923
[TBL] [Abstract][Full Text] [Related]
8. [No comparison with NRTI. Tenofovir is robust against resistance trouble].
MMW Fortschr Med; 2002 Apr; 144 Suppl 1():65. PubMed ID: 12043079
[No Abstract] [Full Text] [Related]
9. Tenofovir and abacavir combination therapy: lessons learned from an urban clinic population.
Gilliam BL; Sajadi MM; Amoroso A; Davis CE; Cleghorn FR; Redfield RR
AIDS Patient Care STDS; 2007 Apr; 21(4):240-6. PubMed ID: 17461718
[TBL] [Abstract][Full Text] [Related]
10. The prevalence and determinants of the K65R mutation in HIV-1 reverse transcriptase in tenofovir-naive patients.
Winston A; Mandalia S; Pillay D; Gazzard B; Pozniak A
AIDS; 2002 Oct; 16(15):2087-9. PubMed ID: 12370512
[TBL] [Abstract][Full Text] [Related]
11. Tenofovir, equivalence, and noninferiority.
Parienti JJ
JAMA; 2004 Oct; 292(16):1951; author reply 1951-2. PubMed ID: 15507576
[No Abstract] [Full Text] [Related]
12. Tenofovir ready for approval.
AIDS Patient Care STDS; 2001 Jul; 15(7):399. PubMed ID: 11483167
[No Abstract] [Full Text] [Related]
13. Cambodia: can a drug provide some protection?
Cohen J
Science; 2003 Sep; 301(5640):1660-1. PubMed ID: 14500956
[No Abstract] [Full Text] [Related]
14. Less than the sum of its parts: failure of a tenofovir-abacavir-Lamivudine triple-nucleoside regimen.
Kuritzkes DR
J Infect Dis; 2005 Dec; 192(11):1867-8. PubMed ID: 16267755
[No Abstract] [Full Text] [Related]
15. CD4 count improvement following tenofovir to abacavir switch in a patient with persistent lymphopenia despite an undetectable viral load.
Condoluci DV; Andrews M; Luber AD
AIDS Read; 2008 Aug; 18(8):410-2. PubMed ID: 18770899
[TBL] [Abstract][Full Text] [Related]
16. Tenofovir disoproxil fumarate.
Kumar A
Drugs; 2003; 63(15):1609-10. PubMed ID: 12887267
[No Abstract] [Full Text] [Related]
17. Long-term follow-up of patients with initial early virologic failure after being treated with once-daily tenofovir/abacavir/lamivudine.
Khanlou H; Farthing C
AIDS Patient Care STDS; 2006 Sep; 20(9):604-5. PubMed ID: 16987045
[No Abstract] [Full Text] [Related]
18. Tenofovir gel studied.
AIDS Patient Care STDS; 2002 Aug; 16(8):401-2. PubMed ID: 12227991
[No Abstract] [Full Text] [Related]
19. Can AIDS drug also prevent HIV infection?
AIDS Read; 2004 Jan; 14(1):14. PubMed ID: 14959699
[No Abstract] [Full Text] [Related]
20. [First nucleotide analog on the market. New drug for the pretreated patient].
MMW Fortschr Med; 2002 Apr; 144 Suppl 1():84. PubMed ID: 12043094
[No Abstract] [Full Text] [Related]
[Next] [New Search]
